- 询价
- 2025年11月24日
14 年金牌会员
企业认证
- 详细信息
- 文献和实验
- 技术资料
- 器官来源：
胰腺
- 细胞形态：
上皮样
- 相关疾病：
腺癌
- ATCC Number：
CRL-2557™
- 库存：
大量
- 年限：
77 years adult
- 生长状态：
贴壁生长
- 物种来源：
人
- 是否是肿瘤细胞：
0
- 运输方式：
冻存运输
| Designations: | Panc 05.04 | ||
| Depositors: | EM Jaffee | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens deposited as human | ||
| Morphology: | epithelial |
||
| Source: | Organ: pancreas Disease: adenocarcinoma |
||
| Cellular Products: | cytokeratins 7 and 18 [50655 ] | ||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Isolation: | Isolation date: May 5, 1995 | ||
| Tumorigenic: | Yes | ||
| Oncogene: | K-ras + | ||
| Antigen Expression: | MHC class I +; MHC class II - [50655 ] Blood type B; Rh+ |
||
| Age: | 77 years adult | ||
| Gender: | female | ||
| Ethnicity: | White | ||
| Comments: | Panc 05.04 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a female with pancreatic adenocarcinoma. The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655 ] The cells have a reported plating efficiency of 100%. [50655 ] |
||
| Propagation: | ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 20 Units/ml human recombinant insulin, 85%; fetal bovine serum, 15% Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
||
| Subculturing: | Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:5 is recommended Medium Renewal: Add media once per week. Fluid change one to two times per week. |
||
| Preservation: | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
||
| Doubling Time: | 46 hrs | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 |
||
| References: | 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 | ||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
流式细胞术上样盲点
Preclinical Development of AS04
Recent knowledge on vaccine-induced immunity led to the development of vaccine Adjuvant Systems specially designed and adapted to vaccine needs. AS04 is such a tailored Adjuvant System developed by GlaxoSmithKline Biologicals. This chapter
电话15309255122 QQ:1578302142 传真029-85237916 联系人 寇小姐 EPR-04 DGR-M1 MK-01P EPM-4C GKR-M2 EPM-4CT EVM-05C EPM-04 AK-01D 5A CKR-81T ECR-3 MPR-53 RG-6T-96 MK-03P EPR-03 GKRS-02F EVM-3 DGRD-01 EPM-0X FKR
技术资料暂无技术资料 索取技术资料
Panc 05.04
询价
